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Neuropsychological assessment of cognitive disorders 
in patients with fi bromyalgia, rheumatoid arthritis, 
and systemic lupus erythematosus
Lucylle Fróis de Melo1, Sérgio Leme Da-Silva2
ABSTRACT
Introduction: This study assesses the possible existence of cognitive disorder associated with chronic diseases [fi bromyalgia 
(FM), rheumatoid arthritis (RA) and lupus (SLE)], and the infl uence of the variables age, educational level and psychiatric 
symptoms on those disorders. Materials and methods: The patients were referred by the Rheumatology Outpatient Clinic 
of the Hospital Universitário de Brasília (HUB), with ages ranging from 30 to 80 years, and were divided into the follow-
ing three groups: FM, 13 patients; RA, 13 patients; and SLE, 11 patients. Their performance in the neuropsychological 
tests of memory, language, executive functions and neuropsychiatric inventory was assessed considering their type of 
chronic disease, educational level and age. In addition, the cutoff points of cognitive normality of population samples were 
compared with the patients’ performances. Results: The cognitive disorders were shown to be associated with the three 
diseases studied, but with signifi cant differences between them. Conclusion: The variables studied (low educational level 
and advanced age) were associated with various degrees of impairment in the different cognitive functions in the three 
pathological groups. However, FM and SLE groups showed signifi cantly higher means of the neuropsychiatric symptoms 
of anxiety, irritability and hallucinations than the RA group in the neuropsychiatric inventory.
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© 2012 Elsevier Editora Ltda. All rights reserved.
CHRONIC PAIN DISEASES AND THEIR 
COGNITIVE ASPECTS
Fibromyalgia
Fibromyalgia (FM) is considered a musculoskeletal syndrome of 
chronic and diffuse pain, because of its large number of symp-
toms. It is diagnosed in the presence of generalized pain for three 
months, in combination with pain in at least 11 of 18 tender point 
sites on digital palpation, according to the American College of 
Rheumatology.1 
Pain in FM is different from any other sensorial impression, 
because it is characterized not only by the sensory-discrimina-
tion dimension, but also by the important affective-emotional 
component, constituted by the affective-motivational dimen-
sion of pain.2
In FM, the central nervous system activity is modulated by 
psychological variables, which contribute to the establishment 
of an abnormal response to pain, such as cognitive distortions, 
excessive attention to noxious stimuli, inadequate attitudes 
for managing pain, and emotional instability when recalling 
painful experiences.2 The sympathetic autonomic nervous sys-
tem is hyperactive during all the time, especially during sleep, 
a phase when several neurotransmitters, hormones and anti-
bodies, such as serotonin, substance P, growth hormone, and 
cortisol, are synthesized or regulated. Thus, some metabolic 
disorders originate in the transitions of the non-REM sleep 
stages, mainly in stage 4, which is the last stage preceding REM 
sleep, a phase with high cerebral activity, characterized by 
dreaming and memory consolidation. Patients with FM show 
no injury in the tissues affected by pain, but have metabolic 
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changes, such as high concentrations of substance P in the 
cerebrospinal fl uid and low concentrations of pain-inhibiting 
neurotransmitters, which cause high sensitivity.3 
The chronicity of FM affects not only patients’ quality of 
life, but also their social relations, habits and routines, causing 
an increase in the psychological abnormalities common to FM, 
especially depressive states and psychiatric disorders.4
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic, autoimmune, chronic 
infl ammatory disease, which affects the joints and has systemic 
manifestations, such as morning stiffness, fatigue, and weight 
loss. The involvement of other organs reduces life expectancy 
by fi ve to ten years. Disease progression makes the patients 
unable to perform their daily-life activities.5,6 
Patients with RA can have cognitive disorders due to the dis-
ease itself or their chronic pain condition. Depression is a factor 
constantly present, infl uencing patients’ quality of life. In the initial 
RA stages, symptoms of anxiety also occur.7 However, the previ-
ous personality and social stress are the two most important aspects 
regarding the appearance of psychological disorders in RA.8
Psychological disorders also develop in association with 
physical impairment. However, the pharmacological treatment 
of RA does not affect the psychiatric fi ndings, which require 
other resources.8
Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a chronic disease of 
unknown cause. It comprises autoimmune and infl ammatory 
processes in a multisystem form, often affecting the central, 
peripheral and autonomic nervous system, generating neuro-
logical impairment, and neuropsychiatric and psychofunctional 
syndromes, such as convulsions, headache, organic cerebral 
syndrome, and psychosis. Neurological impairment can occur 
simultaneously with other symptoms, or after disease onset.9–11 
SLE can result from immune damage, or from several 
systemic manifestations. The scientifi c community has reached 
consensus regarding the multifactorial etiology of the disease, 
suggesting the following causative factors: hormonal, genetic, 
infectious, environmental, and psychological.9–12 However, 
several researchers have associated worsening of SLE primar-
ily with psychological factors.11–13 
The SLE diagnosis should be established based on at least 
four of the following 11 criteria: malar rash, discoid rash, 
photosensitivity, oral and nasal ulcers, arthritis, serositis, renal 
disorder, neurological disorder, hematologic disorder, immu-
nologic disorder, and antinuclear antibodies.14
Researchers have reported a 75% incidence of cognitive disor-
ders, anxiety and depression in SLE.9 According to them, the cogni-
tive disorders did not differ among the patients when comparing 
gender, race, disease duration, disease activity, or any clinical mani-
festation variables. In addition, no relation was identifi ed between 
the cognitive disorders and the medications used by the patients.
This study aimed at assessing the existence of cognitive 
disorders associated with FM, SLE, and RA, by use of neu-
ropsychological tests, having the cutoff points of clinical 
consensus as parameters of normality. Cognitive performance 
was assessed considering the infl uence of the variables age, 
educational level, and psychiatric symptoms.
MATERIALS AND METHODS
This was a pilot study approved by the Ethics Committee on 
Research with Human Beings of the Health Sciences School 
of the Universidade de Brasília (protocol #20/2010). 
Data collection was performed at the Hospital Universitário 
de Brasília of the Universidade de Brasília (HUB/UnB), with 
patients referred by the Rheumatology Outpatient Clinics, who 
voluntarily submitted to the study, after being informed about 
the research and providing written informed consent. 
This study assessed 37 patients divided into three groups, as 
follows: FM, 13 patients; RA, 13 patients; and SLE, 11 patients. 
Their ages ranged from 30 to 80 years, and only one patient 
was from the male gender. The educational level ranged from 
one to 12 years of schooling. 
The following neuropsychological tests were used: Mini-
Mental State Examination (MMSE);15 digits forward (DF) 
and digits backwards (DB) subtests, and Logical Memory I 
(LM-I) and II (LM-II) of the Wechsler Memory Scale (WMS);16 
Similarities subtest (SIM) of the Wechsler Adult Intelligence 
Scale (WAIS-III);17 Phonemic Verbal Fluency test (VFT-Pho) 
and Semantic Verbal Fluency test – Animals (VFT-SeAn) and 
Fruits (VFT-SeFr) categories;18 clock drawing test (CDT);19 
Five-Points test (5PT);20 and neuropsychiatric inventory (NPI).21
The possibility of association between chronic pain diseases 
(FM, RA, and SLE) and cognitive disorders was assessed by 
using the correlation between the patients’ performance in the 
neuropsychological tests applied and the cutoff points considered 
normal in such tests, reported in the literature. The association of the 
cognitive disorders with the following variables were also assessed: 
age, educational level, psychiatric symptoms, and disease duration. 
Statistical analysis
Data analysis was performed by use of robust statistics, which is 
the set of techniques used to attenuate the effect of the outliers and 
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that preserves the distribution form more adherent to empirical 
data. According to Wilcox,22 means can be distorted by outliers, 
not refl ecting the accuracy of the central value of the data. Thus, 
that author has recommended the use of the median, which is an 
extreme form of trimmed mean, in which any value 20% above 
or below the fi xed point is ruled out, and the central value of the 
original data is more accurately obtained. Thus, our study used 
the Keselman technique,23 in which, at fi rst, the scores are ordered 
from the lowest to the highest, and 20% of the lowest and high-
est data are removed. Then the remaining scores replace those 
that were removed. These are the so-called trimmed scores. The 
analysis of variance of the trimmed scores was performed by us-
ing the following tests: a) Kruskal-Wallis test, a nonparametric 
method to test the equality of the medians of the population with 
more than two groups; in this study, it was aimed at assessing the 
existence of differences between the medians of the three groups 
of diseases (FM, SLE, and RA) regarding cognitive performance, 
in addition to assessing the infl uence of age and educational level 
on the presence of psychiatric symptoms; b) Mann-Whitney test, 
used to assess whether two independent samples originate from 
the same distribution. In this regard, all patients were organized 
in two groups according to the following variables: age (young 
adults, up to 49 years; and elderly, up to 80 years); educational 
level (low, up to fi ve years of schooling; and medium-high, at least 
six years of schooling); and duration of disease (early discovery, 
up to three years when diagnosed; and late discovery, more than 
four years when diagnosed).
RESULTS
The nonparametric Kruskal-Wallis test showed signifi cant 
differences between the groups of chronic diseases. 
The group of patients with FM showed a lower performance as 
compared with those of the other groups in the following subtests: 
LM-I of the WMS [(K = 7.73) *P < 0.05]; SIM of the WAIS-III 
[(K = 22.94) *P < 0.05]; VFT-SeAn [(K = 5.98) *P < 0.05], and 
DB of the WMS [(K = 11.02) *P < 0.05]. In addition, patients 
with FM showed an increase in the perseverance error rate in the 
5PT [K = 9.41 *P < 0.05] as compared with the other groups. 
The group of patients with RA showed a lower performance 
as compared with those of the other groups in the following 
subtests: CDT [(K = 16.43) *P < 0.05], VFT-Pho [(K = 7.12) 
*P < 0.05], and 5PT [(K = 9.16) *P < 0,05]. FM and RA groups 
had performances below the cutoff point expected in the fol-
lowing subtests: LM-I of the WMS, VFT-Pho, VFT-SeAn, 
VFT-SeFr, and 5PT (Table 1). 
Table 1
Neuropsychological performance of the groups of chronic rheumatological diseases according to the type of disease and signifi cant 
differences between the groups according to the nonparametric Kruskal-Wallis test
Tests (cutoff points)Ref. RA (n = 13) FM (n = 13) SLE (n = 11) Statistics and P value
MMSE (< 24)1 23.07 (1.70) 23.07 (1.84) 23.45 (1.77) (K = 4.05) P = 0.13
LM-I (< 7.5)2 6.80 (0.72) 6.11 (1.24) 7.77 (1.21) (K = 7.73) *P < 0.05
LM-II (4.5)2 4.61 (0.84) 4.42 (1.09) 7.59 (3.35) (K = 5.34) P = 0.94
SIM (< 10)3 11.15 (1.72) 10.61 (3.04) 18.18 (1.47) (K = 22.94) *P < 0.05
CDT (< 6)4 7.61 (1.89) 7.84 (1.51) 9.63 (0.50) (K = 16.43) *P < 0.05
VFT-Pho (< 30)5 19.38 (6.87) 22.15 (4.41) 26.45 (6.81) (K = 7.12) *P < 0.05
VFT-SeAn (≤ 15)5 11.07 (2.39) 10.61 (2.18) 12.90 (1.81) (K = 5.98) *P < 0.05
VFT-SeFr (≤ 15)5 11.61 (2.18) 11.53 (0.51) 12.72 (2.37) (K = 2.00) P = 0.36
5PT (≤ 15)6 12.76 (3.60) 13.76 (3.56) 18.00 (2.79) (K = 9.16) *P < 0.05
5PT-perseverance6 3.38 (3.47) 6.46 (4.19) 1.54 (1.43) (K = 9.41) *P < 0.05
DF (< 6)7 9.76 (1.92) 10.15 (1.34) 8.90 (0.94) (K = 4.09) P = 0.12
DB (< 4)7 11.15 (1.72) 10.61 (3.04) 18.18 (1.47) (K = 11.02) *P < 0.05
NPI hallucinations 0.30 (0.75) 1.84 (1.67) 2.0 (1.94) (K = 8.14) *P < 0.01
NPI irritability 0.53 (1.45) 1.84 (2.15) 2.81 (2.04) (K = 7.36) *P < 0.02 
NPI anxiety 2.46 (1.50) 3.30 (1.10) 3.45 (1.80) (K = 6.04) *P < 0.05
Patients’ performance in the neuropsychological tests. MMSE: Mini-Mental State Examination; LM-I: logical memory I subtest of the Wechsler Memory Scale; LM-II: logical memory II subtest of the Wechsler 
Memory Scale; SIM: similarities subtest of the Wechsler Adult Intelligence Scale; CDT: clock drawing test; VFT-Pho: phonemic verbal fl uency test; VFT-SeAn: semantic verbal fl uency test – animals category; 
VFT-SeFr: semantic verbal fl uency test – fruits category; 5PT: Five-Points test; DF: digits forward subtest of the Wechsler Memory Scale; DB: digits backwards subtest of the Wechsler Memory Scale; NPI: 
neuropsychiatric inventory. Organized according to the types of pathologies (RA, FM, and SLE) with signifi cant differences indicated by K in the Kruskal-Wallis test, and signifi cance in *(P > 0.05). References 
of the cutoff points: 1) Bertolucci, Brucki, Campacci and Juliano (1994); 2) Hodges & Patterson (1995); 3) Nascimento (1998); 4) Sunderland et al. (1989); 5) Bayles, Kasniak (1987); 6) Bayles, Kasniak 
(1987); Andreas et al. (1992); 7) Regard, Strauss & Knapp (1982); 8) Nascimento (1998). 
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Table 2
Age and years of schooling of patients in the chronic 
rheumatological diseases (RA, FM, and SLE) according to 
the nonparametric Kruskal-Wallis test
Age Years of schooling
RA (n = 13) 55.07 (8.33) 1.84 (0.68)
FM (n = 13) 53.30 (3.85) 2.07 (0.75)
SLE (n = 11) 37.54 (5.90) 2.27 (0.78)
Statistics and P value (K = 20.28) *P < 0.05 (K = 2.03) P = 0.36
Mean, standard deviation, and differences between medians with signifi cant differences indicated 
by K in the Kruskal-Wallis test and signifi cance in *(P > 0.05). 
The SLE group showed the best performances in the LM-I 
and DB of the WMS, SIM of the WAIS-III, CDT, VFT-Pho, 
VFT-SeAn, VFT-SeFr, and 5PT subtests. However, regarding 
the cutoff points of the cognitive performance normality, such 
performances were below the expected range in the VFT-Pho, 
VFT-SeAn, and VFT-SeFr subtests. In addition, SLE and FM 
groups showed symptom frequency rates signifi cantly greater 
than that of the RA group regarding hallucination [(K = 8.14) 
*P < 0.01] and irritability [(K = 7.36) *P < 0.02], as well as 
regarding symptom intensity, in which anxiety [(K = 6.04) 
*P < 0.05] was signifi cantly elevated in both groups (Table 1). 
The other psychiatric symptoms (disillusion, restlessness, 
dysphoria, euphoria, apathy, disinhibition, and aberrant motor 
activity) did not differ between the groups regarding intensity 
or frequency.
In addition, a nonparametric analysis was performed to 
assess whether the mean age and educational level differed in 
the diseases studied. The Kruskal-Wallis test revealed that RA, 
FM, and SLE did not differ regarding the educational level. 
Regarding age, however, the SLE group signifi cantly differed 
from the others [(K = 20.28) *P < 0.05], possibly due to its 
lower mean age (Table 2).
Table 3
Neuropsychological performance of patients with chronic rheumatologic diseases organized according to their ages, and signifi cant 
differences according to the nonparametric Mann-Whitney test
Tests (cutoff points)Ref. Young adults (n = 19) Elderly (n = 18) Statistics and P value
MMSE (< 24)1 24.11 (1.60) 22.84 (1.74) (Z = -2.13) *P < 0.05
LM-I (< 7.5)2 7.33 (1.29) 6.39 (1.03) (Z = -2.14) *P < 0.05
LM-II (4.5)2 6.52 (2.96) 4.39 (0.96) (Z = -2.29) *P < 0.05
SIM3 15.55 (3.86) 10.68 (2.45) (Z = -3.65) P = 0.70
CDT (≤ 6)4 9.11 (1.07) 7.52 (1.80) (Z = -3.24) *P < 0.05
VFT-Pho (≤ 30)5 25.11 (6.64) 19.94 (5.61) (Z = -2.63) *P < 0.05
VFT-SeAn (≤ 15)6 12.44 (2.17) 10.52 (2.09) (Z = -2.49) *P < 0.05
VFT-SeFr (< 15)6 12.55 (2.09) 11.31 (1.45) (Z = -1.68) P = 0.09
5PT7 16.50 (3.41) 12.94 (3.73) (Z = -2.51) *P < 0.05
5PT-perseverance 3.38 (3.48) 4.42 (4.15) (Z = -0.66) P = 0.51
DF (< 6)8 9.55 (1.54) 9.73 (1.55) (Z = -0.37) P = 0.07
DB (< 4)8 9.33 (1.57) 10.10 (1.62) (Z = -1.54) P = 0.12
Patients’ performance in the neuropsychological tests. MMSE: Mini-Mental State Examination; LM-I: logical memory I subtest of the Wechsler Memory Scale; LM-II: logical memory II subtest of the Wechsler 
Memory Scale; SIM: similarities subtest of the Wechsler Adult Intelligence Scale; CDT: clock drawing test; VFT-Pho: phonemic verbal fl uency test; VFT-SeAn: semantic verbal fl uency test – animals category; 
VFT-SeFr: semantic verbal fl uency test – fruits category; 5PT: Five-Points test; DF: digits forward subtest of the Wechsler Memory Scale; DB: digits backwards subtest of the Wechsler Memory Scale. Organized 
according to age groups with signifi cant differences indicated by Z in the Mann-Whitney test and signifi cance in *(P > 0.05) between the groups of young and elderly adults. References of the cutoff points: 
1) Bertolucci, Brucki, Campacci and Juliano (1994); 2) Hodges & Patterson (1995); 3) Nascimento (1998); 4) Sunderland et al. (1989); 5) Bayles, Kasniak (1987); 6) Bayles, Kasniak (1987); Andreas et al. 
(1992); 7) Regard, Strauss & Knapp (1982); 8) Nascimento (1998).
The nonparametric Mann-Whitney test showed a signifi -
cant difference in performance between the groups divided 
according to age in the following subtests: MMSE [(Z = -2.13) 
*P < 0.05], LM-I of the WMS [(Z = -2.14) *P < 0.05], LM-II of 
the WMS [(Z = -2.29) *P < 0.05], CDT [(Z = -3.24) *P < 0.05], 
VFT-Pho [(Z = -2.63) *P < 0.05], VFT-SeAn [(Z = -2.49) 
*P < 0.05], and 5PT [(Z = -2.51) *P < 0.05]. In all those sub-
tests, younger patients performed better (Table 3).
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Table 4
Neuropsychological performance of patients with chronic rheumatologic diseases organized according to their educational levels, 
and signifi cant differences according to the nonparametric Mann-Whitney test
Tests (cutoff points)Ref. Low educational level (n = 22) Medium-high educational level (n = 15) Statistics and P value
MMSE (< 24)1 22.90 (1.60) 24.26 (1.75) (Z = -2.36) *P < 0.05
LM-I (< 7.5)2 6.47 (0.99) 7.40 (1.40) (Z = -1.99) *P < 0.05
LM-II (4.5)2 4.50 (0.93) 6.80 (3.19) (Z = -2.03) *P < 0.05
SIM (≤ 10)3 11.86 (3.28) 14.80 (4.45) (Z = -2.10) *P < 0.05
CDT (≤ 6)4 7.86 (1.80) 8.93 (1.27) (Z = -2.13) *P < 0.05
VFT-Pho (≤ 30)5 20.40 (6.16) 25.46 (6.20) (Z = -2.36) *P < 0.05
VFT-SeAn (≤ 15)6 10.81 (2.17) 12.40 (2.26) (Z = -1.98) *P < 0.05
VFT-SeFr (≤ 15)6 11.36 (1.64) 12.73 (1.94) (Z = 1.99) *P < 0.05
5PT (15)7 13.36 (3.65) 16.60 (3.69) (Z = -2.26) *P < 0.05
5PT-perseverance 3.50 (3.97) 4.53 (3.64) (Z = -1.34) P = 0.17
DF (< 6)8 9.50 (1.68) 9.86 (1.30) (Z = -1.18) P = 0.23
DB (< 4)8 9.63 (1.76) 9.86 (1.45) (Z = -0.83) P = 0.40
 Patients’ performance in the neuropsychological tests. MMSE: Mini-Mental State Examination; LM-I: logical memory I subtest of the Wechsler Memory Scale; LM-II: logical memory II subtest of the Wechsler Memory 
Scale; SIM: similarities subtest of the Wechsler Adult Intelligence Scale; CDT: clock drawing test; VFT-Pho: phonemic verbal fl uency test; VFT-SeAn: semantic verbal fl uency test – animals category; VFT-SeFr: semantic 
verbal fl uency test – fruits category; 5PT: Five-Points test; DF: digits forward subtest of the Wechsler Memory Scale; DB: digits backwards subtest of the Wechsler Memory Scale. Organized into groups according 
to the educational level, with signifi cant differences indicated by Z in the Mann-Whitney test and signifi cance in *(P > 0.05) between the groups of low and medium-high educational level. References of the cutoff 
points: 1) Bertolucci, Brucki, Campacci and Juliano (1994); 2) Hodges & Patterson (1995); 3) Nascimento (1998); 4) Sunderland et al. (1989); 5) Bayles, Kasniak (1987); 6) Bayles, Kasniak (1987); Andreas et al. 
(1992); 7) Regard, Strauss & Knapp (1982); 8) Nascimento (1998). 
The Mann-Whitney test showed signifi cant differences be-
tween the low and medium-high educational level groups in the 
following subtests: MMSE [(Z = -2.36) *P < 0.05], LM-I of the 
WMS [(Z = -1.99) *P < 0.05], ML-II of the WMS [(Z = -2.03) 
*P < 0.05], SIM of the WAIS-III [(Z = -2.10) *P < 0.05], CDT 
[(Z = -2.13) *P < 0.05], VFT-Pho [(Z = -2.36) *P < 0.05], VFT-SeAn 
[(Z = -1.98) *P < 0.05], VFT-SeFr [(Z = 1.99) *P < 0.05], and 
5PT [(Z = -2.26) *P < 0.05]. 
All the results of the subtests indicate a signifi cantly lower 
performance in the low-educational-level group (Table 4).
Finally, regarding disease duration, the Mann-Whitney test 
showed no signifi cant difference in the cognitive performances 
in the neuropsychological tests, when the patients were divided 
into the two groups of early and late discovery of chronic pain 
diseases (*P > 0.05). 
DISCUSSION
The results confi rm the existence of cognitive disorders associ-
ated with FM, SLE, and RA. Patients with RA showed a re-
duced performance in the tests assessing the cognitive spheres 
regarding visual-constructional apraxia (CDT and VFT-Pho), 
that is, the ability to draw a picture based on a visual memory 
reference and phonemic verbal fl uency. We can conclude that 
those patients have apraxic cognitive disorders possibly due to 
physical and motor impairment of RA in addition to the cogni-
tive defi cits observed in that disease. The reduced phonemic 
fl uency observed in such patients might be related to the social 
stress present in RA.8
Patients with FM, on the other hand, had defi cits in the 
tests assessing operational memory (LM-I, VFT-SeAn, 
SIM, and DB), as well as perseverance errors in 5PT, which 
also refer to executive function disorders. A reduction in 
concentration and memory loss have already been shown in 
patients with FM,24 and those cognitive changes in attention 
are directly related to defi cits in operational memory and 
executive function.25
Patients with SLE had the best performances as compared 
with the other two groups. However, the performance of the 
SLE group was below the cutoff point of cognitive normality in 
the phonetic and semantic verbal fl uency tests (VFT-Pho, VFT-SeAn, 
and VFT-SeFr). In addition, it showed a signifi cantly higher 
rate of psychiatric disorders (anxiety, irritability, and hallucina-
tion). Studies with patients with SLE have shown that 75% of 
them have cognitive deterioration associated with psychiatric 
disorders, such as depression, anxiety, and irritability.9,11
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Regarding the types of chronic diseases, no difference in 
the educational level was observed. However, regarding age, 
the SLE group differed signifi cantly from the other groups 
due to its lower mean age. Healthy elderly when compared 
with youngsters regarding cognitive aspects, show a mild and 
generalized slowness, in addition to accuracy loss,26,27 which 
might have infl uenced the results of this study, favoring the SLE 
group as compared with the RA and FM groups in that aspect. 
When assessing the age groups without considering the 
types of chronic diseases, young adults performed better in 
all tests as compared with the elderly. The literature confi rms 
the low cognitive performance of the elderly with no disease, 
suggesting that such decline results primarily from aging, 
characterizing a normal decline in the functioning of memory 
basic processes. When daily life activities of the elderly decline 
along with their cognitive performance, however, a nosological 
entity should be present.26,27
Regarding the data related to the infl uence of the educa-
tional level, this study showed a reduced cognitive performance 
mainly in the operational memory sphere of the low-educational- 
level group, suggesting that memory tests can dependent on 
the educational level.25 
The coinciding performances below the cognitive normal-
ity cutoff points in the phonetic and semantic verbal fl uency 
tests of the FM and SLE groups are likely to be associated 
with the high intensity and frequency rates of psychiatric 
disorders, such as hallucination, irritability and anxiety, found 
in the NPI of those two groups, especially in the SLE group, 
which had the greatest rates. Such data are in accordance 
with the fi ndings of other studies indicating that patients 
with psychiatric disorders have diffi culties strongly related 
to functional defi cits that refl ect on academic performance, 
productivity, work, and social, familial and affective relation-
ships.28 Such functional defi cits associated with anxiety occur 
similarly in other diseases, such as dementia, potentiating the 
impaired participation or the engagement in essential activi-
ties of daily social life, leading to a reduction in performing 
tasks involving attention, psychomotricity, verbal and non-
verbal memory, comprehension, executive functions, verbal 
fl uency, and planning.29
According to some studies, the increase in cognitive dys-
functions of SLE is not related to the duration of the chronic 
rheumatologic disease,30 confi rming our results regarding 
disease duration and its infl uence on the patients’ performance 
in cognitive tests.
In patients with FM, the increased release of substance P is 
infl uenced by the low levels of serotonin and the presence of non-
restoring or superfi cial sleep. Those patients can have as much 
as a three-fold increase in substance P levels as compared with 
healthy individuals.31 It is worth emphasizing that the ascending 
serotonergic pathways, coincidently those whose levels are re-
duced in patients with FM, project themselves to the raphe nuclei 
and from those to the thalamus and areas innervated by the medial 
forebrain bundle, with emphasis to the hippocampus – important 
areas for the storage of operational and long-term memories.32
Several studies have shown that substance P has different 
effects related to learning in rats33 and fi sh,34 ranging from a 
facilitating effect, when applied immediately or up to three 
days after the training for learning acquisition, to the lack of 
effect on memory consolidation, when applied from the fourth 
day of training onward.35 Thus, the defi cits in operational 
memory and executive functions found in patients with FM 
in this study can be somehow related to the reduced serotonin 
levels in that disease.
A consensus recently published has revealed the importance 
of rehabilitation programs that use the cognitive-behavioral 
therapy, aiming at improving chronic pain diseases such as 
FM and SLE.36
Neuropsychological studies on chronic pain diseases and 
their cognitive dysfunctions are very important, because the 
deep knowledge on the cognitive aspects of a certain disease 
provides effective clues for the construction of rehabilitation 
programs.37,38 Cognitive stimulation is possible because of ce-
rebral plasticity, and rehabilitation with cognitive exercises can 
modulate plastic processes in the brain, infl uencing positively 
the functional organization of neural connections involved in 
memory.37,38 Finally, cognitive stimulation through rehabilita-
tion programs can reduce the cognitive defi cits found, thus 
promoting better quality of life or even preventing the aggra-
vation of cognitive and emotional defi cits, which have been 
identifi ed in patients with RA, FM, and SLE. 
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